Management attributes the Q1 revenue impact and lowered full-year outlook to significant coding and reimbursement uncertainty surrounding the Inspire V system. Performance was bolstered by gross profit expansion driven by a higher sales mix of the Inspire V system, despite the broader reimbursement challenges. The WISER program, a new Medicare AI-reviewed prior authorization pilot in six states, created procedural delays that acted as a direct headwind to Q1 revenue. Strategic focus has pivoted toward provi ...